News|Articles|November 2, 2001

Pharmaceutical Technology-11-02-2001
Volume 25
Issue 11

Tablet Relaxation and Physiocomechanical Stability of Lactose, Microcrystalline Cellulose, and Dibasic Calcuim Phosphate

Author(s)Ruey-ching Hwang, Chris E. Friedrich, Gretchen R. Peck

The authors discuss the physiocomechanical characteristics of three commonly used pharmaceutical excipients and describe the effects of variables on their physiocomechanical stability.

External Link - article-3375.pdf

Articles in this issue

almost 25 years ago

Article

blank

almost 25 years ago

Article

Truth in Outsourcing

almost 25 years ago

Article

Manufacturers Face Challenges and Regulatory Changes

almost 25 years ago

Article

One-Step Aqueous Enteric Coating Systems: Scale-Up Evaluation

almost 25 years ago

Article

Filter Integrity Testing in Liquid Applications, Revisited Part II

almost 25 years ago

Article

Outsourcing Outlook

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance. Subscribe to Pharmaceutical Technology and never miss an industry breakthrough.

Subscribe

Related Content

FDA concept | Concept of the Food and Drug Administration. Magnifier glass, folder and clock | Image Credit © Sviatlana - stock.adobe.com

What Does Overton's FDA Nomination Mean for Drug Reviews?

ByZachary Zubulake

August 19th 2026

Silver Spring, MD, USA - June 25, 2022: The FDA White Oak Campus, headquarters of the United States Food and Drug Administration, a federal agency of the Department of Health and Human Services (HHS) | © Tada Images - stock.adobe.com (521699065)

Ecopipam's D1 Receptor Approach Signals New Pediatric Neuroscience Pathway

ByZachary Zubulake

August 19th 2026

Adeno-associated viruses, 3D illustration | Image Credit: ©Dr_Microbe -stock.adobe.com

Andelyn Biosciences Partners with Queen's University on GM2 Gangliosidosis Gene Therapy

BySusan Haigney

August 18th 2026

A treatment for erythropoietic protoporphyria and X-linked protoporphyria is pending approval from the FDA.

Dersimelagon Acquisition Highlights Shift Toward Late-Stage Rare Disease Licensing

ByZachary Zubulake

August 18th 2026

How China's biotech surge is reshaping US drug licensing, manufacturing control, and FDA data trust, the key shifts pharma professionals must track.

PharmTech Explained: China's Biotech Rise Signals New Risks for US Manufacturers

ByZachary Zubulake,Saharsh Davuluri,John Stanford

August 18th 2026

Tablet Relaxation and Physiocomechanical Stability of Lactose, Microcrystalline Cellulose, and Dibasic Calcuim Phosphate

Articles in this issue

Related Content

What Does Overton's FDA Nomination Mean for Drug Reviews?

Ecopipam's D1 Receptor Approach Signals New Pediatric Neuroscience Pathway

Andelyn Biosciences Partners with Queen's University on GM2 Gangliosidosis Gene Therapy

Dersimelagon Acquisition Highlights Shift Toward Late-Stage Rare Disease Licensing

PharmTech Explained: China's Biotech Rise Signals New Risks for US Manufacturers

Trending on Pharmaceutical Technology

A Capsule-in-Capsule Platform for Multi-Phase Release of Liquid and Solid Formulations

PharmTech Explained: China's Biotech Rise Signals New Risks for US Manufacturers

Q&A: Why Sponsors Are Turning to Mixed FSP/FSO Models

Andelyn Biosciences Partners with Queen's University on GM2 Gangliosidosis Gene Therapy

Dersimelagon Acquisition Highlights Shift Toward Late-Stage Rare Disease Licensing